Active substances
Aluminuium + Hydrocortisone + Lidocaine + Zinc oxide
- SFDA 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| XYLOPROCT OINT | 3.5, 0.275, 5, 18 % | Rectal ointment · Rectal use | 20 Tube | SAR 14.55 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| XYLOPROCT OINT | 3.5, 0.275, 5, 18 % | Rectal ointment · Rectal use | 20 Tube | SAR 14.55 | NCE · Prescription | Aspen Pharma Trading Limited | Withdrawn by MAH · Not Marketed |
| XYLOPROCT SUPP | 50, 5, 60, 400 mg | Suppository · Rectal use | 10 Blister | SAR 14.15 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| XYLOPROCT SUPP | 50, 5, 60, 400 mg | Suppository · Rectal use | 10 Blister | SAR 14.15 | NCE · Prescription | Aspen Pharma Trading Limited | Withdrawn by MAH · Not Marketed |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.